InMode Ltd. (NASDAQ:INMD) Stock Has Consensus Target Price of $16.00

InMode Ltd. (NASDAQ:INMD) has received a consensus rating of “Hold” from the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $16.00.

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of InMode in a report on Thursday, August 6th.

Institutional Trading of InMode

Several institutional investors have recently made changes to their positions in INMD. Inspire Investing LLC grew its holdings in shares of InMode by 6.1% during the 1st quarter. Inspire Investing LLC now owns 19,366 shares of the healthcare company’s stock valued at $265,000 after acquiring an additional 1,111 shares in the last quarter. Plan A Wealth LLC lifted its stake in shares of InMode by 8.4% in the 3rd quarter. Plan A Wealth LLC now owns 19,201 shares of the healthcare company’s stock valued at $272,000 after purchasing an additional 1,481 shares during the last quarter. IFP Advisors Inc bought a new stake in shares of InMode during the 2nd quarter worth about $31,000. Blue Trust Inc. boosted its position in InMode by 69.4% during the first quarter. Blue Trust Inc. now owns 5,567 shares of the healthcare company’s stock worth $76,000 after purchasing an additional 2,281 shares during the period. Finally, First Trust Advisors LP boosted its holdings in shares of InMode by 19.6% during the 1st quarter. First Trust Advisors LP now owns 24,911 shares of the healthcare company’s stock worth $341,000 after buying an additional 4,084 shares during the period. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Stock Performance

NASDAQ:INMD opened at $14.21 on Monday. The business’s fifty day moving average price is $14.74 and its 200 day moving average price is $14.39. The firm has a market capitalization of $816.79 million, a price-to-earnings ratio of 11.55 and a beta of 2.03. InMode has a 1-year low of $12.72 and a 1-year high of $16.67.

InMode (NASDAQ:INMD) last announced its quarterly earnings data on Wednesday, August 5th. The healthcare company reported $0.35 EPS for the quarter, hitting analysts’ consensus estimates of $0.35. InMode had a return on equity of 11.99% and a net margin of 20.69%. The firm had revenue of $95.59 million during the quarter, compared to analyst estimates of $94.89 million. During the same period last year, the company posted $0.47 EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year.

About InMode

InMode Ltd. is an Israel-based medical technology company that develops, manufactures and markets energy-based platforms for aesthetic and medical treatments. Its technologies are designed to support minimally invasive and noninvasive procedures in areas such as skin rejuvenation, facial and body contouring, hair removal, intimate health and other soft-tissue applications.

The company’s product portfolio includes radiofrequency and other energy-based systems sold under brands such as Morpheus8, BodyTite, FaceTite, Forma and Lumecca.